PA8607001A1 - Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 - Google Patents
Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3Info
- Publication number
- PA8607001A1 PA8607001A1 PA20048607001A PA8607001A PA8607001A1 PA 8607001 A1 PA8607001 A1 PA 8607001A1 PA 20048607001 A PA20048607001 A PA 20048607001A PA 8607001 A PA8607001 A PA 8607001A PA 8607001 A1 PA8607001 A1 PA 8607001A1
- Authority
- PA
- Panama
- Prior art keywords
- rent
- optionally replaced
- polyhaloalkyl
- alkylcarbonyl
- nr6br7b
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 3
- -1 CARBOXYL Chemical class 0.000 abstract 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UN COMPUESTO DE FORMULA UN N-OXIDO, UNA SAL DE ADICION ACEPTABLE DESDE EL PUNTO DE VISTA FARMACEUTICO, UNA AMINA CUATERNARIA Y UNA FORMA ESTEREOQUIMICAMENTE ISOMERICA DEL MISMO, DONDE EL ANILLO A REPRESENTA FENILO, PIRIDILO, PIRIMIDINILO, PIRIDAZINILO O PIRAZINILO; R1 REPRESENTA HIDROGENO; ARILO; FORMILO; ALQUILCARBONILO C1-6; ALQUILO C1-6; ALQUILOXICARBONILO C1-6; ALQUILO C1-6 SUSTITUIDO CON FORMILO, ALQUILCARBONILO C1-6 ALQUILOXICARBONILO C1-6, ALQUILCARBONILOXI C1-6; O ALQUILOXI-C1-6-ALQUILCARBONILO C1-6 SUSTITUIDO OPCIONALMENTE CON ALQUILOXICARBONILO C1-6; X REPRESENTA UN ENLACE DIRECTO; -(CH2)N3- O -(CH2)N4-X1A-X1B-; R2 REPRESENTA CICLOALQUILO C3-7; FENILO; UN HETEROCICLO MONOCICLICO DE 4,5,6 O 7 MIEMBROS QUE CONTIENE AL MENOS UN HETEROATOMO SELECCIONADO DE O, S, O N; BENZOXAZOLILO O UN RADICAL DE FORMULA DONDE DICHO SUSTITUYENTE R2 PUEDE ESTAR OPCIONALMENTE SUSTITUIDO; R3 REPRESENTA HALO; HIDROXI; ALQUILO C1-6 SUSTITUIDO OPCIONALMENTE; ALQUENILO C2-6 O ALQUINILO C2-6, CADA UNO SUSTITUIDO OPCIONALMENTE; POLIHALOALQUILO C1-6; ALQUILOXI C1-6 SUSTITUIDO OPCIONALMENTE; POLIHALOALQUILOXI C1-6; ALQUILTIO C1-6; POLIHALOALQUILTIO C1-6; ALQUILOXICARBONILO C1-6; ALQUILCARBONILOXI C1-6; ALQUILCARBONILO C1-6; POLIHALOALQUILCARBONILO C1-6, CIANO; CARBOXILO; ARILOXI; ARILOXI; ARILTIO; ARILCARBONILO; NR6BR7B; C(=O)-NR6BR7B; -NR5-C(=O)-NR6BR7B; -NR5-C(=O)-R5; -S(=O)N1-R8A; -NR5- S(=O)N1-R8A; -S-CN; -NR5-CN;R4 REPRESENTA HIDROGENO; HALO; HIDROXI; ALQUILO C1-4 SUSTITUIDO OPCIONALMENTE; ALQUENILO C2-4 O ALQUINILO C2-4, CADA UNO SUSTITUIDO OPCIONALMENTE; POLIHALOALQUILO C1-3; ALQUILOXI C1-4 SUSTITUIDO OPCIONALMENTE; POLIHALOALQUILOXI C1-3; ALQUILTIO C1-4; POLIHALOALQUILTIO C1-3; ALQUILOXICARBONILO C1-4;ALQUILCARBONILOXI C1-4; ALQUILCARBONILO C1-4; POLIHALOALQUILCARBONILO C1-4; NITRO; CIANO; CARBOXILO; NR10R11; C(=O)NR10R11; -NR5-C(=O)-NR10R11; -NR5-C(=O)-R5;-S(=O)N1-R12; -NR5-S(=O)N1-R12; -S-CN; -NR5-CN; SU USO, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0350310 | 2003-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8607001A1 true PA8607001A1 (es) | 2005-05-10 |
Family
ID=34112425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20048607001A PA8607001A1 (es) | 2003-07-16 | 2004-07-15 | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7560458B2 (es) |
| EP (1) | EP1658292B1 (es) |
| JP (1) | JP2009514782A (es) |
| KR (1) | KR20060120393A (es) |
| CN (1) | CN100404536C (es) |
| AP (1) | AP2006003486A0 (es) |
| AR (1) | AR045698A1 (es) |
| AT (1) | ATE370142T1 (es) |
| AU (1) | AU2004260738B2 (es) |
| BR (1) | BRPI0412596A (es) |
| CA (1) | CA2531333A1 (es) |
| DE (1) | DE602004008303T2 (es) |
| DK (1) | DK1658292T3 (es) |
| EA (1) | EA010109B1 (es) |
| ES (1) | ES2290754T3 (es) |
| IL (1) | IL173139A (es) |
| JO (1) | JO2460B1 (es) |
| MX (1) | MXPA06000540A (es) |
| NO (1) | NO20060678L (es) |
| NZ (1) | NZ545058A (es) |
| PA (1) | PA8607001A1 (es) |
| PL (1) | PL1658292T3 (es) |
| PT (1) | PT1658292E (es) |
| TW (1) | TW200524935A (es) |
| WO (1) | WO2005012307A1 (es) |
| ZA (1) | ZA200600385B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| CN103169708B (zh) | 2002-07-29 | 2018-02-02 | 里格尔药品股份有限公司 | 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
| CA2531333A1 (en) * | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| JP4607879B2 (ja) * | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン |
| EA010160B1 (ru) * | 2003-09-18 | 2008-06-30 | Конформа Терапьютикс Корпорейшн | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения |
| MX2007003325A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa. |
| AR051090A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| AU2005286728A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| JP5149009B2 (ja) | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体 |
| AR051093A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa |
| EP1830837B1 (en) | 2004-09-20 | 2013-09-04 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CA2577588C (en) | 2004-10-29 | 2013-09-10 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting bicyclic pyrimidine derivatives |
| WO2006076442A2 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| RU2485106C2 (ru) | 2005-06-08 | 2013-06-20 | Райджел Фамэсьютикэлз, Инк. | Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| CN101743242A (zh) * | 2007-06-29 | 2010-06-16 | 苏尼西斯制药有限公司 | 用作raf激酶抑制剂的杂环化合物 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2011144742A1 (en) | 2010-05-21 | 2011-11-24 | Chemilia Ab | Novel pyrimidine derivatives |
| EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
| SG11201404234YA (en) | 2012-01-28 | 2014-08-28 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives |
| WO2013131609A1 (en) | 2012-03-07 | 2013-09-12 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| WO2014135245A1 (en) | 2013-03-05 | 2014-09-12 | Merck Patent Gmbh | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| CN105026398B (zh) * | 2013-03-05 | 2018-05-18 | 默克专利股份公司 | 用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物 |
| WO2014180524A1 (en) | 2013-05-06 | 2014-11-13 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
| WO2016087665A2 (en) * | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
| WO2017035528A1 (en) | 2015-08-27 | 2017-03-02 | Nantneuro, Llc | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| WO2017156527A1 (en) | 2016-03-11 | 2017-09-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease |
| JP2022520671A (ja) | 2019-02-08 | 2022-03-31 | フリークエンシー・セラピューティクス・インコーポレイテッド | 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬 |
| WO2025104079A1 (en) * | 2023-11-17 | 2025-05-22 | Helmholtz-Zentrum für Infektionsforschung GmbH | Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5962594A (ja) * | 1982-09-30 | 1984-04-10 | Ss Pharmaceut Co Ltd | ３，５―ジ置換―トリアゾロピリミジン誘導体 |
| US20020040031A1 (en) * | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system |
| US6737085B2 (en) * | 2000-11-01 | 2004-05-18 | Tokiwa Phytochemical Co., Ltd. | Apocynum venetum extract for use as antidepressant |
| WO2002050073A1 (en) * | 2000-12-19 | 2002-06-27 | Smithkline Beecham P.L.C. | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| CA2531333A1 (en) * | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
-
2004
- 2004-07-12 CA CA002531333A patent/CA2531333A1/en not_active Abandoned
- 2004-07-12 MX MXPA06000540A patent/MXPA06000540A/es active IP Right Grant
- 2004-07-12 EA EA200600258A patent/EA010109B1/ru not_active IP Right Cessation
- 2004-07-12 EP EP04766189A patent/EP1658292B1/en not_active Expired - Lifetime
- 2004-07-12 NZ NZ545058A patent/NZ545058A/en not_active IP Right Cessation
- 2004-07-12 BR BRPI0412596-7A patent/BRPI0412596A/pt not_active IP Right Cessation
- 2004-07-12 DK DK04766189T patent/DK1658292T3/da active
- 2004-07-12 JP JP2006519926A patent/JP2009514782A/ja not_active Withdrawn
- 2004-07-12 ES ES04766189T patent/ES2290754T3/es not_active Expired - Lifetime
- 2004-07-12 CN CNB2004800201486A patent/CN100404536C/zh not_active Expired - Fee Related
- 2004-07-12 JO JO200496A patent/JO2460B1/en active
- 2004-07-12 PL PL04766189T patent/PL1658292T3/pl unknown
- 2004-07-12 PT PT04766189T patent/PT1658292E/pt unknown
- 2004-07-12 DE DE602004008303T patent/DE602004008303T2/de not_active Expired - Lifetime
- 2004-07-12 WO PCT/EP2004/051455 patent/WO2005012307A1/en not_active Ceased
- 2004-07-12 US US10/564,844 patent/US7560458B2/en not_active Expired - Fee Related
- 2004-07-12 AT AT04766189T patent/ATE370142T1/de active
- 2004-07-12 AP AP2006003486A patent/AP2006003486A0/xx unknown
- 2004-07-12 AU AU2004260738A patent/AU2004260738B2/en not_active Ceased
- 2004-07-12 KR KR1020057024541A patent/KR20060120393A/ko not_active Ceased
- 2004-07-15 AR ARP040102496A patent/AR045698A1/es not_active Application Discontinuation
- 2004-07-15 PA PA20048607001A patent/PA8607001A1/es unknown
- 2004-07-15 TW TW093121066A patent/TW200524935A/zh unknown
-
2006
- 2006-01-12 IL IL173139A patent/IL173139A/en not_active IP Right Cessation
- 2006-01-13 ZA ZA200600385A patent/ZA200600385B/en unknown
- 2006-02-10 NO NO20060678A patent/NO20060678L/no not_active Application Discontinuation
-
2008
- 2008-09-16 US US12/211,361 patent/US20090036471A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060205721A1 (en) | 2006-09-14 |
| ZA200600385B (en) | 2007-05-30 |
| BRPI0412596A (pt) | 2006-09-19 |
| AU2004260738B2 (en) | 2009-07-16 |
| JP2009514782A (ja) | 2009-04-09 |
| ES2290754T3 (es) | 2008-02-16 |
| IL173139A (en) | 2010-04-29 |
| TW200524935A (en) | 2005-08-01 |
| PT1658292E (pt) | 2007-10-25 |
| PL1658292T3 (pl) | 2008-01-31 |
| CN100404536C (zh) | 2008-07-23 |
| US20090036471A1 (en) | 2009-02-05 |
| AR045698A1 (es) | 2005-11-09 |
| WO2005012307A1 (en) | 2005-02-10 |
| EP1658292A1 (en) | 2006-05-24 |
| EA200600258A1 (ru) | 2006-06-30 |
| NZ545058A (en) | 2008-05-30 |
| DE602004008303T2 (de) | 2008-05-08 |
| DE602004008303D1 (de) | 2007-09-27 |
| CN1823068A (zh) | 2006-08-23 |
| ATE370142T1 (de) | 2007-09-15 |
| AU2004260738A1 (en) | 2005-02-10 |
| KR20060120393A (ko) | 2006-11-27 |
| JO2460B1 (en) | 2009-01-20 |
| US7560458B2 (en) | 2009-07-14 |
| NO20060678L (no) | 2006-02-10 |
| IL173139A0 (en) | 2006-06-11 |
| AP2006003486A0 (en) | 2006-02-28 |
| EA010109B1 (ru) | 2008-06-30 |
| EP1658292B1 (en) | 2007-08-15 |
| MXPA06000540A (es) | 2006-03-30 |
| CA2531333A1 (en) | 2005-02-10 |
| DK1658292T3 (da) | 2007-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8607001A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
| PA8791601A1 (es) | Compuestos de biciclolactama sustituida | |
| PA8606901A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
| AR071763A1 (es) | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos | |
| CO5680403A2 (es) | Antagonistas de mchr1r | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| CO2018003565A2 (es) | Compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53 | |
| SV2009003281A (es) | Inhibidores espiro cetona de acetil-coa carboxilasa.0 | |
| ECSP088638A (es) | Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados | |
| GT200600159A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| TW200738641A (en) | Pyrazole based LXR modulators | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| GT200600164A (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| PE20071236A1 (es) | Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina | |
| AR073774A1 (es) | Compuestos antibioticos oxazolidinona triciclicos | |
| GT200400146A (es) | Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso | |
| AR072726A1 (es) | Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c | |
| CR8756A (es) | Derivados de acido carboxilico bencimidazolona | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| DOP2006000045A (es) | Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica | |
| GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| AR040126A1 (es) | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| PA8589801A1 (es) | Aminoalcoxiindoles |